Cardiology
Conference Coverage
‘Modest’ benefit for post-MI T2D glucose monitoring
Equivocal results were seen with regard to the best method to monitor blood glucose after myocardial infarction.
Conference Coverage
NACMI: Clear benefit with PCI in STEMI COVID-19 patients
Angiography fell off but door-to-balloon times haven’t suffered, even with the pandemic, according to initial results from the North American...
News
Female cardiac advantage essentially lost after MI
The protective effect against coronary heart disease that women have for an initial event was not maintained for recurrent CHD events including...
Conference Coverage
T2D treatments create tension between glycemic and cardiovascular goals
Recent society guidelines clash on whether metformin or newer drug classes should start first when treating patients with type 2 diabetes.
News
AHA issues new scientific statement on heart health for LGBTQ adults
The AHA urges routine check of cardiovascular health and efforts to combat discrimination in the health care setting for LGBTQ adults.
Conference Coverage
Benefit of rivaroxaban after limb revascularization greatest in those with comorbid CAD
New results from the landmark VOYAGER PAD trial identify which patients benefit most from adding rivaroxaban after limb revascularization.
News
The socioeconomic revolving door of 30-day heart failure readmissions
Racial disparities in 30-day HF readmissions stem partly from variation in economic status of residential neighborhoods, regardless of hospital...
News
Surgeon general pushes for improved hypertension control
“We cannot wait to deal with this epidemic of uncontrolled high blood pressure” that affects more than 82 million American, U.S. Surgeon General...
Original Research
Retrospective Review on the Safety and Efficacy of Direct Oral Anticoagulants Compared With Warfarin in Patients With Cirrhosis
A retrospective chart review of adult patients with cirrhosis taking either DOACs or warfarin found no statistically significant differences in...
Conference Coverage
Dapagliflozin’s CKD performance sends heart failure messages
The recently reported DAPA-CKD trial results focused on patients with renal disease, but the findings also resonate for heart failure clinicians...